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The Joint National Committee (JNC-8) current guidelines recommend providers use 
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) as 
first line medications for the treatment of hypertension. As with any medication, there are 
associated risks and benefits. A brief review of the literature found conflicting information in 
terms of what effect, if any, ACEI or ARB’s have on breast cancer. Several studies have 
theorized that ACEI/ARBs may have anti-tumor properties, specifically in terms of breast cancer 
while other studies indicate an increased risk or no association with breast cancer.  
A review of literature through the Harley French Library at the University of North 
Dakota was conducted to determine the risk versus benefits of ACEI/ARBs in relevance to breast 
cancer. Using the databases CINAHL and Pub Med, years 2012-2018, a search using the terms 
ace inhibitors, angiotensin receptor blockers, and breast cancer was ensued. A total of 167 
articles were found through CINAHL, nine of them relevant to this topic. Pub Med revealed 57 
total articles, two appropriate for use in this paper. 
Developed from an Objective Structured Clinical Examination (OSCE) on the 
management of newly diagnosed hypertension in a 60-year-old female, the purpose of this 






 ACEI/ARBs AND BREAST CANCER RISK 
 
4 
The Use of Ace Inhibitors/Angiotensin II Receptor Blockers in Hypertension and 
Associated Risk of Breast Cancer in Women 
In the United States, hypertension and breast cancer are high on the list of illnesses 
contributing to the morbidity/mortality of women. Overall, 1 in 3 Americans have hypertension, 
specifically after age 64 more women than men have hypertension (American Heart Association, 
2013). Untreated, hypertension can lead to multiple conditions including myocardial infarction, 
heart failure, renal failure, loss of vision, stroke, and peripheral vascular disease (Woo & 
Robinson, 2016). Another commonly occurring disease affecting women is breast cancer. Breast 
cancer is listed as the most commonly occurring neoplastic disease and leading cause of cancer 
death among women (Chang et al., 2016; Raebel et al., 2017).  
The Joint National Committee guidelines on hypertension management list angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) as first-line 
medications used in the treatment of hypertension (Woo & Robinson, 2016). In 2013 there were 
a combined 10+ million prescriptions for ACEI/ARBs filled in the United States alone, making 
these classes some of the most commonly prescribed medications (Delmare, 2015). As with any 
medication there are associated risks and benefits to their use. Initial research indicated a 
possible increased risk for development of breast cancer in women who use ACEI/ARBs for 
management of their hypertension. However, controversial data now exists in terms of an 
associated increased risk versus protective benefit against breast cancer in women who use these 
medications for the management of hypertension.  
Developed from a family nurse practitioner Objective Structured Clinical Examination 
(OSCE) exam involving the management of newly diagnosed hypertension in a 60-year old 
woman, this paper reviews current literature to determine the risk versus benefits of ACEI/ARBs 
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and associated risk of breast cancer among women using these medications for the management 
of hypertension. 
Case Report 
 XX is a 60-year old Caucasian female with a medical history significant for newly 
diagnosed hypertension who presented to the clinic for follow-up after starting lisinopril, an 
ACEI, 20 mg by mouth once daily three weeks ago. XX endorsed feeling well since starting 
lisinopril, however did report having developed a dry, non-productive cough. She denied having 
symptoms of upper respiratory illness such as fever, chills, sweats, sinus congestion, rhinorrhea, 
sore throat, shortness of breath, or chest pain associated with the cough. She also denied having 
headaches, dizziness, lightheadedness, or edema. XX stated she had been monitoring her blood 
pressures at home since starting lisinopril, finding them to consistently be 140/80’s. 
Additionally, XX has made lifestyle changes including following a low salt, low fat diet along 
with incorporating exercise into her weekly routine. Other positive findings during review of 
systems with XX discovered occasional “heart burn” symptoms relieved with Tums. She denied 
having chest pressure/pain/discomfort, heaviness, palpitations, shortness of breath, nausea, 
vomiting, or other symptoms indicating acute coronary syndrome. 
  XX’s family history is strong for cardiovascular disease with her sister and brother both 
diagnosed with hypertension; her father has had open heart surgery. XX endorsed having a 
personal 20 pack/year cigarette smoking history, a habit she quit 10 years ago. She is married, 
with adult children, and retired from the nursing profession. Current medications reported by 
patient include a daily multivitamin and lisinopril 20 mg by mouth once daily. 
 This clinic visit found XX to be afebrile, her blood pressure elevated at 160/98, pulse 
regular and strong at 80 beats per minute, respiratory rate of 20. XX’s physical exam was 
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thoroughly negative for any concerning findings including wheezing, rales, irregular heart beat, 
skin changes, neurological deficits, or edema.  
  Many patients are unable to tolerate taking ACEI due to the development of a dry cough. 
This common side effect is thought to be associated with bradykinin, an anti-inflammatory, 
vasodilating mediator broken down into it’s active fragments by ACEI (Woo & Robinson, 2016). 
Angiotensin II receptor blockers have similar anti-hypertensive actions as ACEI (Woo & 
Robinson, 2016). Unlike ACEI, ARB’s do not affect bradykinin nullifying the risk of the 
commonly ACEI associated cough (Woo & Robinson, 2016).  
Given the review of systems and physical assessment findings, the cause of XX’s cough 
is most likely this common side effect of lisinopril (Woo & Robinson, 2016). Following the 
JNC-8 guidelines, XX’s cough can be easily remedied by changing the ACEI, lisinopril, to the 
ARB, losartan to continue appropriate management of her hypertension (Woo & Robinson, 
2016). 
When considering medication management for any disease process, it is imperative that 
health care providers consider patient risk factors, side effects and associated risks of the 
medications prescribed. While XX’s past medical history is most significant for cardiovascular 
disease, her age and smoking history put her at risk for breast cancer as well. Plan of care for XX 
includes continued lifestyle changes, discontinuation of lisinopril, initiating losartan to manage 
hypertension, and routine health maintenance such as immunizations, osteoporosis, breast and 
colon cancer screening. A complete review of XX’s OSCE can be found in Appendix A. 
Pathophysiology 
Blood pressure is regulated, in part, through the body’s renin angiotensin system (RAS) 
(Chae et al., 2011; Woo & Robinson, 2016). The RAS system contains both angiotensin I and 
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angiotensin II receptors (Vinson, Barker, & Puddefoot, 2012). Angiotensin-converting enzymes 
change inactive angiotensin I into active angiotensin II, a key regulator in the secretion of 
aldosterone and thus salt/water retention and vascular tone (Lee et al., 2012; Napeleone et al., 
2011). Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduce 
blood pressure through inhibition of vasoconstrictive angiotensin II and decreased production of 
aldosterone there by reducing the overall circulating intravascular volume (Chae et al., 2013; 
Woo & Robinson, 2016). Utilizing this understanding of RAS/cancer cell pathophysiology 
researchers aim to seek the potential benefits of ACEI/ARBs in cancer treatment. See Appendix 
B for complete RAS system pathophysiology. 
In addition to decreasing hypertension, angiotensin-converting enzyme inhibitors offer 
renal protection, which is a benefit to diabetic patients with proteinuria (Woo & Robinson, 
2016). Angiotensin II receptor blockers do not prevent diabetic nephropathy but do offer the 
benefit of slowing the progression of renal disease (Woo & Robinson, 2016). These 
antihypertensive medications also offer benefit to patients with congestive heart failure (Chae et 
al., 2013). 
Breast cancer cells have been found to contain full components of the renin angiotensin 
system, showing signs of increased cancer cell proliferation and angiogenesis in the presence of 
angiotensin II (Chae et al., 2013; Vinson, Barker, & Puddefoot, 2012). Angiotensin II, among 
its’ many actions, works as a growth factor in both normal and breast cancer epithelial cells 
(Chae et al., 2013; Lee et al., 2012; Napoleone et al., 2011). Angiotensin II regulation is also 
involved in programmed cell death, a key component in the treatment of cancer (Vinson, Barker, 
& Puddefoot, 2012). When both angiotensin I and II receptors are blocked, there is inhibition of 
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tumor cell proliferation, angiogenesis, and metastasis (Napoleone et al., 2011; Vinson, Barker, & 
Puddefoot, 2012).  
Literature Review 
The literature contains conflicting information in terms of what effect, if any, ACEI or 
ARB’s have on breast cancer. Several studies have indicated that ACEI/ARBs may have anti-
tumor properties, specifically in terms of breast cancer, while other studies indicate an increased 
risk or no association in the development of breast cancer. Multiple variables were noted 
throughout the studies in this literature review. When considering data obtained from any study, 
it is imperative that the results are based on consistent, reliable, and reproducible information and 
must consider confounding variables. Variables other than only the use of ACEI/ARBs such as 
age, gender, race, genetics, weight, smoking history, and socio-economic status should be 
considered when determining any positive or negative association with medication use and breast 
cancer. Ultimately, providers must weigh the benefits ACEI/ARBs provide in terms of 
hypertension management and risk reduction against the potential risks these classes of 
medication present when prescribing. 
Associated Risk 
Research and data have established the effectiveness of ACEI/ARBs in treating 
hypertension (Lonati & Morganti, 2014). Ganz, Habel, Weltzein, Caan, & Cole (2011) reviewed 
data from the 2000 Life After Cancer Epidemiology (LACE) study to determine risk between 
antihypertensive medications such as ACEI and breast cancer recurrence in women. Recognizing 
a wide array of modifiable and non-modifiable variables influence cancer development and 
recurrence, authors of this study found ACEI to cause a significant increased risk of breast 
cancer recurrence (HR=1.56, 95% CI, 1.02, 2.39).  
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Sorenson et al. (2013) corroborated the LACE data. Utilizing a prospective cohort study 
platform, seven years of data from 18,733 women with pre-diagnosed, non-metastatic breast 
cancer was reviewed. Looking specifically at the rate of breast cancer recurrence in the setting of 
previous ACEI-ARB use, researchers considered several confounding variables (age, 
menopause, cancer staging, etc.) in determining the study outcomes. Women who used ACEI 
were found to have a slightly increased risk of breast cancer recurrence (HR=1.2, 95% CI, 0.97-
1.4) over those women who did not use ACEI. Additionally, researchers of this study determined 
ACEI/ARBs do not offer any protective benefit against cancer recurrence.  
The MCC-Spain Study revealed slightly different data than Sorenson et al. and Ganz et 
al. found. This large, population-based case-control study reviewed 1,736 breast cancer cases, 
seeking to discover any association between the use of anti-hypertensive medications and breast 
cancer development (Gomez-Acebo et al., 2016). Researchers discovered an increased risk of 
breast cancer in premenopausal women who used ARBs for hypertension management (OR 4.27, 
95% CI, 1.32-13.84). Conversely postmenopausal women were found to have no increased risk 
of breast cancer associated with the use of ACEI.  
Sipahi et al. (2011) questioned what effect ACEI have on cancer occurrence and cancer 
death. In this large study, information from meta-analysis of 14 studies (range 23,291-61,744 
participants) looked specifically at randomized control trials involving ACEI with mention of 
cancer occurrence. Findings from this large study indicate ACEI do not offer protective benefits 
against cancer or cancer related death. In contrast to other studies reviewed, data gathered in this 
study is not gender specific nor does it address menopausal status of any women in the study. 
Importantly, in terms of this author’s review, data specific to breast cancer alone was not 
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reviewed; this study looked at generalized cancer occurrence and death. Furthermore, while 
ACEI were reviewed, ARBs were conspicuously absent from this meta-analysis. 
Data collected by Song et al. (2017) found conflicting data. This meta-analysis reviewed 
PubMed, Embase, and the Cochrane Library, ultimately selecting 11 studies with a total of 4,964 
participants. Their research discovered significant reduction in cancer recurrence in those 
patients taking ACEI/ARBs and diagnosed with urinary tract, colorectal, pancreatic, and prostate 
cancer via a significant reduction in cancer recurrence. Data indicates those with breast or 
hepatocellular cancer do not experience this same reduction in recurrence when taking 
ACEI/ARBs.  
Two large case-control studies based on data from a national cancer data base in Taiwan 
agreed with Sipahi et al. Separate studies by Lee et al. (2012) and Chang et al. (2016) found no 
increased risk of breast cancer in women who used ACEI/ARBs (age >50). Similar to other 
studies mentioned here, authors recognized the presence of multiple variables associated with the 
development of breast cancer. Unfortunately, when determining outcomes, variables considered 
between the two studies were inconsistent.  
Data from U.S. based research agreed with results from the studies in Taiwan. In 2011, the 
United States Food and Drug Administration (FDA) supported the position that ARBs, 
specifically, do not increase the risk of cancer (Townsend, 2017). Additionally, U.S. based Up to 
Date (2017), an extensive current medical data base, determined through a review of two large 
meta-analyses, the use of ACEI/ARBs is not associated with an increase risk of cancer. This data 
corroborates findings of previously mentioned studies in this review.   
Benefits of Use 
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 Several studies reviewed through this literature review determined the use of 
ACEI/ARBs offer a protective benefit against the development of many cancers. Yoon et al. 
(2011) based their research on epidemiologic studies, finding inconsistent results in terms of 
ACEI/ARBs and the risk of cancer. This study reviewed 3,970 articles, ultimately selecting 10 
cohort studies (3,611,694 individuals) and 14 case-control studies for analysis. Overall, authors 
of this study determined there is no association between the use of ACEI/ARBs and overall risk 
of cancer (RR 0.96, 95% CI, 0.90-1.03). However, through a sensitivity analysis, they did find 
there may be beneficial effects with the use of either ACEI/ARBs in terms of cancer risk when 
the included conventional case-control studies were removed from the mix. These conflicting 
results indicate the need for large randomized control trials that specifically look at this possible 
benefit.  
Napoleone et al. (2011) sought to discover if blocking the RAS system would potentially 
have any controlling influence on tissues in metastatic breast cancer cells. Researchers found 
ACEI down-regulate the expression of tissue factor in metastatic human breast carcinoma cells, 
thereby inhibiting cancer cell proliferation, migration, tumor growth, and metastasis. These 
findings, discovered in a controlled laboratory setting, indicate this beneficial effect is directly 
related to inhibition of the RAS by the actions of ACEI, suggesting a new potential strategy for 
combined methods in the treatment of cancer. Despite the presence of limitations including lack 
of human variables such as age, gender, genetics, and organ specific cancers, the strength of 
results indicate a need for further well designed research on the effects of ACEI/ARBs in cancer 
research. 
Contradicting Sipahi et al., Lonati and Morganti (2012) found larger meta-analysis 
studies indicating antagonists of the RAS system may actually protect against cancer incidence 
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and progression. Rabel et al. (2017) upheld these findings through a large retrospective cohort 
study. Data collected from Kaiser Permanente, the largest non-profit, private, integrated health 
care delivery system in the United States included 90,078 women >55 years of age using ACEI 
for management of hypertension. Looking specifically at the risk of breast cancer associated with 
long term use of calcium channel blockers or ACEI researchers found an increased duration of 
ACEI use (between 1-12 years) correlated with a protective association against breast cancer.  
Seeking to determine the risk associated with ACEI/ARBs and the development of solid 
tumor cancers, such as breast cancer, Chae et al. (2011) used a case-control study format to 
analyze data from a veteran affairs hospital. This small study (703 patients, mean age 59.1 years) 
looked at 168 patients who had used ACEI/ARB for at least six months. This group had a 
statistically significant lower incidence in cancer recurrence (ACE/ARB use: 15% recurrence 
rate; Non-use: 23%). The final conclusion of this study determined patients who used 
ACEI/ARBs had a significantly lower rate of breast cancer recurrence than non users. Similar 
results were obtained from the Nurses’ Heath Study (NHS) and Nurses’ Health Study II (NHSII) 
studies (Devore et al., 2015). Using data collected from 210,641 U.S. registered nurses, 
researchers found the use ace inhibitors imparts a decreased risk of breast cancer on women 
using the medication for hypertension.  
Conclusion 
The renin angiotensin system is a powerful mediator of multiple key elements of blood 
pressure regulation and homeostasis. Key players in the RAS system include angiotensin I and II 
(Woo & Robinson, 2016). ACEI/ARBs work to block RAS receptors, thereby effectively 
reducing blood pressure (Woo & Robinson, 2016). It is known that cancer cells contain 
angiotensin I/II receptors; these receptor sites are involved in the proliferation and angiogenesis 
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of cancerous tumors (Vinson, Barker, & Puddefoot, 2012). This knowledge has lead researchers 
to theorize ACEI/ARBs, given their mechanism of action, could have an anti-tumor effect on 
cancer cells. However, a firm answer as to whether or not ACEI/ARBs provide increased risk, 
protective benefits, or have no effect in terms of breast cancer occurrence in women, is cloudy at 
best given the literature reviewed here.  
 The literature presented in this paper contain several inconsistent confounding variables 
whose presence affects the variables being studied. When variables are not adjusted for 
appropriately in a study, confounding factors give a skewed true relationship among the variables 
(Pourhoseingholi, Baghestani, & Vahedi, 2012). There are multiple different variables involved 
in the development of both breast cancer and hypertension. These variables include, but are not 
limited to, ethnicity, age, menopausal status, obesity, smoking history, genetics, physical 
activity, and diet. Considering these confounding factors, it seems difficult to develop a true 
correlation between ACEI/ARBs and breast cancer occurrence. 
 JNC-8 guidelines recommend ACEI/ARBs as first line treatment in managing 
hypertension (Woo & Robinson, 2016). With 32.7% of American women diagnosed with 
hypertension, it is imperative that the safety, efficacy, risks, and potential benefits of these 
medications be thoroughly examined (CDC, 2016). The following points are key to this literature 
review: 
• Untreated, hypertension can have devastating and long term consequences such as stroke, 
cardiovascular disease, and renal failure. ACEI/ARBs effectively reduce these risks (Woo 
& Robinson, 2016). When managing hypertension, it is imperative to prescribe 
medications that will control blood pressure with minimal side effects and risk to patient 
safety. 
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• Selection of medication should be based on optimizing blood pressure control with 
minimal, if any, effects. Researchers have theorized the angiotensin blocking effects of 
ACEI/ARBs may prove to be useful in the prevention or treatment of breast cancer 
(Napoleone et al., 2011). Further research is indicated in this area. 
• The reviewed studies contain varied, inconsistent, confounding variables and research 
methods and more importantly, inconsistent results. There is insufficient research to 
prove the use of ACEI/ARBs in women with hypertension creates an increased risk for 
developing or preventing breast cancer. Given this lack of unequivocal evidence, it is 
reasonable for advanced practice providers to prescribe ACEI/ARBs, knowing the 
benefits of treating hypertension outweigh the low risk of breast cancer occurrence. Per 
the JNC 8 guidelines, ACEI/ARBs should continue to be used as first line treatment of 
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OSCE Write Up 
CC: Hypertension medication-follow up 
HPI: XX is a 60-year-old Caucasian female with a history significant for new diagnosis 
hypertension who presents to the clinic for follow-up appointment after starting Lisinopril 20 mg 
by mouth daily three weeks ago. Patient reports feeling overall well since starting the Lisinopril, 
however she does endorse a new onset of dry cough since beginning the medication. She denies 
signs/symptoms of upper respiratory illness. She has been monitoring her blood pressures at 
home since starting the medication, finding her pressures are typically running 140/80’s. She did 
not bring her blood pressure record with her today. She has been attempting to follow a low salt, 
low fat diet as well as incorporating exercise into her weekly routine. She reports occasional 
“heartburn” symptoms relieved with 1-2 tums. Does not recall factors that increase these 
symptoms. Denies shortness of breath, chest pressure/pain, arm, neck, or jaw pain, 




Medications: Multivitamin 1 tablet daily, Lisinopril 20 mg daily 
Social History: 20 pack/year history, quit 10 years ago, married, retired RN 
Family History: father-cardiovascular disease including “open heart surgery”; Brother-
hypertension; Sister-hypertension 
ROS 
Constitutional: negative for fevers, chills, or sweats. Negative for fatigue.  
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HEENT: Negative for headache, dizziness, lightneadness, ear/eye pain/drainage, sinus 
congestion, epistaxis, sore throat, or dysphagia 
CV: Negative for chest pain/discomfort or palpitations 
Resp: Negative for shortness of breath, wheezing. Positive for cough. 
GI: Negative for n/v/c/d or melena. Positive for “heartburn” 
GU: Negative for dysuria, frequency, incontinence, or hematuria 
Integumentary: Negative for rashes, wounds, bruising 
 
Physical Exam 
Vital Signs: 160/98, P 80, RR 20, T 98.6 
Constitutional: alert and oriented. Pleasant. In no obvious distress. Well nourished. Afebrile. 
HEENT: normocephalic, TM’s normal, external ear normal. EOM’s intact, no redness, drainage. 
Pupils PEARRL. Nares patent bilaterally and without drainage. Oropharynx pink, moist, and 
without exudate. No thyromegaly noted. Neck is soft, supple with normal ROM. 
CV: S1S2, regular rate and rhythm. No edema noted. 
Resp: Lung sounds clear throughout all fields. Normal work of breathing. 
GI: Abdomen is soft, non-tender to palpation 
Integumentary: turgor normal, skin color normal, warm and dry. No bruising, rashes, wounds, 
or petechiae noted 
 
Assessment 
XX is a 60-year-old Caucasian female with a history significant for new diagnosis hypertension 
who presents to the clinic for follow-up appointment after starting Lisinopril 20 mg PO daily 
 ACEI/ARBs AND BREAST CANCER RISK 
 
21 
three weeks ago. Patient reports feeling overall well with starting Lisinopril, however endorses 
new onset of dry cough since starting medication. Lung sounds clear throughout all fields, 
normal work of breathing, afebrile, denies shortness of breath. Likely cause of cough is related to 
common side effect of Lisinopril; low suspicion for infectious etiology. Per patient, blood 
pressures at home consistently running 140/80’s- within JNC 8 guidelines for goal pressures 
given patient’s age. Today’s elevated pressures may be related to anxiety over clinic visit. 
Concerns for GERD given recent history of “heart burn” relieved with Tums.  
Plan 
Hypertension 
1. Will change Lisinopril to Losartan 50 mg PO daily in the AM in hopes this will alleviate 
cough while maintaining normotensive status. 
2. Recommend starting 81 mg Aspirin daily for heart health. 
3. Labs today: CBC, Chem 8 to assess kidney function, Hgb. Baseline EKG. Baseline chest 
x-ray (cardiomegaly). 
4. Reiterate importance of low salt diet, exercise, stress reduction. Maintain a healthy 
weight. 
5. Return to clinic in 3 weeks for repeat Chemistries to assess renal function after starting 
Losartan.  
6. Continue to check blood pressure at the same time each day. Bring blood pressure diary 
to appointment in 3 weeks. Will recheck blood pressure in clinic at that time as well. 
7. Seek immediate care for persistent headaches or acute neurological deficits indicating 
CVA. 
GERD 
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1. Continue TUMS per package directions for infrequent acid reflux symptoms. May use 
OTC Zantac for symptoms as well. Follow the package directions. 
2. If GERD symptoms become persistent, will start PPI vs consistent H2 blocker. 
3. May need to consider EGD. 
4. Instruct patient to monitor for melena, occult blood in stools, hematemesis indicating GI 
bleed. Seek medical care immediately if either of these occur.  
5. Instruct patient to follow a low salt, low fat, low acid diet. Avoid caffeine, spicy foods, 
alcohol, and smoking as these may increase GERD symptoms.  
6. Prop the head of the bed up with 6 inch blocks to help keep gastric acid from entering the 
esophagus. Do not lay down for 30 minutes after eating.  
7. Advise patient when to seek immediate medical attention indicating acute coronary 
syndrome: chest pain, pressure, or discomfort that may radiate to neck, jaw, or arm, 
shortness of breath, nausea/vomiting, sweating. 
Health Maintenance 
1. Mammograms yearly 
2. Fasting serum glucose, cholesterol panel 
3. Yearly influenza vaccination 
4. Pneumonia vaccination after age 65 
5. Dexa scan to monitor mineral bone density 










Table 1. Renin-angiotensin aldosterone system. (Woo & Robinson, 2016). 
